logo-loader

Acerus Pharma reports approval of ESTRACE Generic in Canada

Published: 08:10 20 Nov 2015 EST

ANGLEplc_564f1c687a818
Shares of Acerus have lost more than 75% this year to leave the company with a market value of $27mln.

Acerus Pharmaceuticals (CVE:JV.P) (OTCMKTS:TRLPF), a Canadian pharmaceutical company,  reported approval for its ESTRACE Generic in Canada.

The Toronto, Ontraio-based company said in a statement on Friday that a Notice of Compliance (NOC) has been granted by Health Canada for a generic version of ESTRACE.

"As far as the Company is aware, the product is currently not available on the Canadian market," it said in the statement.

Acerus added that it is closely monitoring the situation and evaluating the possible impact, if any, that a potential launch could have on ESTRACE sales going forward.

Shares of Acerus (OTCMKTS:TRLPF) closed down 8.3% at $0.126 on Thursday. The stock has lost more than three-quaters of its value this year.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

21 minutes ago